AYTU vs. VTVT, ARTV, RNXT, CELU, PEPG, MRSN, BLUE, CUE, AADI, and NBRV
Should you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include vTv Therapeutics (VTVT), Artiva Biotherapeutics (ARTV), RenovoRx (RNXT), Celularity (CELU), PepGen (PEPG), Mersana Therapeutics (MRSN), bluebird bio (BLUE), Cue Biopharma (CUE), Aadi Bioscience (AADI), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry.
Aytu BioPharma vs. Its Competitors
Aytu BioPharma (NASDAQ:AYTU) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation.
In the previous week, Aytu BioPharma had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 5 mentions for Aytu BioPharma and 3 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.62 beat Aytu BioPharma's score of 0.57 indicating that vTv Therapeutics is being referred to more favorably in the news media.
33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 3.6% of Aytu BioPharma shares are held by company insiders. Comparatively, 4.2% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Aytu BioPharma has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.
vTv Therapeutics has a consensus price target of $35.50, suggesting a potential upside of 129.62%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than Aytu BioPharma.
Aytu BioPharma has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.
vTv Therapeutics received 98 more outperform votes than Aytu BioPharma when rated by MarketBeat users. However, 67.11% of users gave Aytu BioPharma an outperform vote while only 57.12% of users gave vTv Therapeutics an outperform vote.
vTv Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -7.62%. Aytu BioPharma's return on equity of -19.30% beat vTv Therapeutics' return on equity.
Summary
Aytu BioPharma and vTv Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Aytu BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aytu BioPharma Competitors List
Related Companies and Tools
This page (NASDAQ:AYTU) was last updated on 6/14/2025 by MarketBeat.com Staff
Buy AYTU Stock Free AYTU Stock Alerts